TrialThe lancet. HIV2025

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.

Carolyn Bolton Moore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.